Phenelzine, supplied as phenelzine sulfate in the selected Nardil oral-tablet record, is a monoamine oxidase inhibitor, or MAOI. Its label describes a qualified role in depression treatment and important medicine, food, blood-pressure, and behavioral risks. The accompanying antidepressant Medication Guide covers only part of that safety information.

Reading an older medicine label can be unsettling when unfamiliar depression terms appear beside serious warnings. This article explains the selected verified Nardil film-coated tablet labeling record, associated with application NDA011909, without treating its historical language as a modern diagnosis. It separates the depression indication from anxiety-related features, explains why different blood-pressure warnings can both be true, and puts reported reactions in context. This is not a complete prescribing reference or a personal treatment plan. The selected record also should not be assumed to remain the latest labeling available when you read this article.

What does the selected Nardil label say phenelzine treats?

The selected label describes treatment of certain depressed patients, not a separate approval for every anxiety presentation. Matching that statement to the product matters, as explained in MVBH’s resources on medicine information documents and Medication Guides and serious risks.

The indication uses the historical terms “atypical,” “nonendogenous,” and “neurotic.” These words describe the depressed patients discussed in this labeling. They are not current diagnostic criteria, explanations of what biologically caused someone’s depression, or categories a reader can reliably assign to themselves. The selected FDA Nardil record is the source for this indication.

Its references to mixed anxiety and depression, phobic features, and “hypochondriacal” features occur within that depression description. The last term is historical wording concerning health-related fears. These references do not independently establish approval for specific phobia, health anxiety, generalized anxiety disorder, or every experience described as anxiety.

The label also says Nardil should rarely be the first antidepressant used and describes a role after nonresponse to more commonly used medicines. That is the label’s qualified treatment role, not a recommended sequence for you. It does not specify a universal number of previous treatments or establish an individual diagnosis of treatment resistance.

Why do medicine and food interactions matter with Nardil?

Interactions are central to Nardil’s safety information because some combinations can cause severe harm. MVBH’s explanations of professional medicine information and patient serious-risk documents clarify why a short patient handout cannot stand in for the interaction sections.

The selected label identifies phenelzine as an inhibitor of monoamine oxidase, an enzyme distributed throughout the body. For readers, the concrete interaction warnings matter more than an elaborate biochemical explanation. Different named combinations carry different concerns in the FDA contraindication and interaction passages:

  • Sympathomimetic agents, including amphetamines and methylphenidate, are linked to the warning about hypertensive crises, meaning dangerous elevations in blood pressure.
  • Serotonergic agents, including sertraline and venlafaxine, are associated with reports of serious and sometimes fatal reactions when combined with MAO inhibitors.
  • Buspirone has a separate combination warning based on reports of elevated blood pressure. Dextromethorphan and certain central nervous system depressants are also named as combinations not to use.
  • Meperidine carries a warning involving severe, potentially fatal reactions. Other MAO inhibitors carry warnings involving hypertensive crises, convulsions, and other severe effects.

These are selected examples, not an interaction checker or a list implying that unnamed products are safe. A familiar medicine name does not make a combination routine.

Food interactions are also distinctive here. The label warns that foods containing high concentrations of tyramine or dopamine can cause hypertensive crises during Nardil treatment. This warning is not limited to prescription combinations. This article provides no food list, dietary regimen, quantities, or timing rules, and cannot replace product-specific dietary counseling.

Why does the label describe both high and low blood pressure?

High-pressure crises and postural low blood pressure are different labeled concerns, not contradictory descriptions. Reading serious-risk language in context alongside the different sections of medicine information helps keep a warning about interactions separate from an adverse reaction.

A hypertensive crisis involves a dangerous rise in blood pressure. Postural hypotension means blood pressure falls with a change in posture, such as becoming upright. The selected Nardil labeling documents both, in different contexts.

Different blood-pressure concerns in the selected Nardil label.
Labeled concernWhat the term describesContext in the Nardil labelWhat it does not establish
Medicine-associated hypertensive crisisDangerously elevated blood pressureWarnings involving sympathomimetic agents and other specified combinationsThat every headache identifies this reaction
Food-associated hypertensive crisisDangerously elevated blood pressureWarning involving foods with high tyramine or dopamine concentrationsA complete dietary plan or personal risk estimate
Postural hypotensionA pressure drop associated with becoming uprightListed among common reactions and addressed in precautionsThat dizziness proves low blood pressure

The precautions say hypotensive effects have occurred in people whose blood pressure was previously high, normal, or low. Having high blood pressure beforehand therefore does not rule out this different concern. Neither the table nor a symptom description can establish what is happening to an individual. It is not a home symptom-sorting method.

Which phenelzine reactions are common, and which are serious?

The selected label separates common reactions from less frequently reported severe events. MVBH’s guides to medicine document sections and interpreting serious-risk information provide context, but the product-specific reaction details come from Nardil’s labeling.

The FDA adverse-reaction section names several experiences as common. Grouping selected examples makes the range easier to understand:

  • Alertness and sleep: dizziness, headache, drowsiness, fatigue, and sleep disturbances, including insomnia or excessive sleeping.
  • Digestive effects: constipation, dry mouth, and other gastrointestinal disturbances.
  • Weight and fluid-related effects: weight gain and edema, meaning swelling associated with fluid accumulation.
  • Blood pressure: postural hypotension, a separate concern from hypertensive crises.
  • Sexual functioning: difficulty reaching orgasm, ejaculatory disturbances, and erectile difficulties.

“Common” does not mean harmless or something a person must simply tolerate. The supplied passage does not give reliable individual percentages for these experiences. A listed reaction also does not prove that the medicine caused a particular person’s new symptom.

The label separately reports severe events occurring less frequently, sometimes in isolated reports. Examples include severe liver injury, convulsions, toxic delirium, manic reactions, and swelling of the glottis, an airway structure. These reports deserve attention without being converted into personal odds. An isolated report cannot tell a reader how likely that event is for them.

What mood and behavior changes does the label warn about?

Nardil’s labeling discusses mood activation and worsening behavior as well as antidepressant-related suicide risk. These are related safety subjects, but not interchangeable. MVBH’s resources on patient serious-risk information and reading medicine documents together help explain their different roles.

The precautions describe hypomania, possible shifts into mania, and increased agitation. Separately, the selected label warns about excessive stimulation in patients with schizophrenia. Increased activity is therefore not automatically evidence of recovery. Nor does a change in energy, by itself, diagnose mania. These concerns appear in the selected FDA labeling.

Separately, the boxed warning describes increased suicidal thinking and behavior compared with placebo among young adults in short-term antidepressant studies. Those studies did not show an increase beyond age 24, but that finding does not mean an older adult has no suicide risk. Depression itself is associated with suicide risk, and the label calls for attention to worsening symptoms and unusual behavior at every age.

The patient information directs prompt contact with the treating professional for new, abrupt, or worsening mood and behavior changes. For immediate danger or a life-threatening reaction, call 911. For suicidal thoughts or crisis support, call or text 988. These emergency and crisis routes are supported by NIMH safety guidance; MVBH is not emergency care.

Why do medical history, procedures, and older age matter?

The selected label places Nardil’s risks in the context of physical health and procedures, not depression alone. Its professional detail complements the patient documents discussed in understanding medicine information and Medication Guide limitations.

The contraindications include a history of liver disease or abnormal liver-function tests, severe kidney impairment or renal disease, and congestive heart failure. These are medicine-specific restrictions, not a complete self-screen. The precautions also address epilepsy because effects on the convulsive threshold may vary. For diabetes, the text discusses possible changes in insulin sensitivity while acknowledging conflicting evidence concerning glucose metabolism and effects on glucose-lowering medicines. These details come from the selected Nardil record.

Procedures matter because the label contains anesthesia-related restrictions and cautions involving general anesthesia, local anesthesia containing sympathomimetic vasoconstrictors, and possible combined blood-pressure-lowering effects with spinal anesthesia. This is a reason for coordinated professional planning, not a basis for a reader to decide when medication should be interrupted.

For adults aged 65 and older, the clinical studies included too few participants to determine whether responses differ from those of younger adults. Other reported clinical experience did not identify differences. Those statements are not equivalent: failure to identify a difference does not establish identical safety or response. Kidney, liver, cardiac, and other health conditions, along with other medicines, remain relevant context.

What can Nardil’s Medication Guide leave unanswered?

The accompanying guide explicitly focuses on suicidal thoughts and actions with antidepressants. It is not a complete Nardil safety guide. That distinction connects MVBH’s broader Medication Guide explanation with the complementary role of professional prescribing information.

Reading that guide alone leaves important product-specific interaction, blood-pressure, adverse-reaction, and medical-history information unanswered. The selected labeling also reports potentially serious symptoms after abrupt withdrawal, including severe psychiatric or neurologic reactions. This article provides no stopping, tapering, switching, or restarting plan.

Neither a label nor this explanation can predict personal benefit or identify the cause of a symptom. NIMH’s treatment principles emphasize individual needs and medical circumstances under qualified professional guidance. Accurate product information supports that discussion; it does not make the decision on its own.

Written by Tim Francis, SUD Content Specialist.

Frequently asked questions

Does this article describe every phenelzine product?

No. It addresses the selected verified Nardil phenelzine sulfate film-coated oral-tablet labeling record. Product-specific statements should remain attached to that record. They do not establish interchangeability, identical ingredients across products, or that this record will remain the latest labeling available. The explanation also does not supply personal prescribing directions.

Does “nonendogenous” explain what caused my depression?

No. “Nonendogenous” is historical wording in the selected Nardil depression indication. It should not be used to decide whether your depression has a biological cause or belongs to a current diagnostic subtype. The wording describes the label’s treatment population; it cannot determine the cause of an individual person’s symptoms.

Why does the Nardil label mention buspirone?

The selected label specifically warns against combining Nardil with buspirone because elevated blood pressure has been reported with MAO inhibitor and buspirone exposure. This is a distinct interaction concern, not evidence that all anxiety medicines carry identical risks. The article cannot establish a safe combination or provide a switching or interaction-management plan.

Does a listed sexual reaction prove Nardil caused my symptoms?

No. The selected label lists sexual disturbances, including orgasm, ejaculation, and erectile difficulties, among common reactions. That establishes a documented possible effect, not the cause of your individual symptoms. Personal medical context and other treatments matter. The reaction list also cannot establish that symptoms are harmless or will necessarily fade.

Does the older-adult evidence show Nardil works the same at every age?

No. The selected record says too few adults aged 65 and older participated in clinical studies to determine whether responses differ. Other clinical experience did not identify a difference, but that is not proof of identical response or safety. It also does not support an age-based prediction for one person.

Phenelzine: Related Guides

For more context, explore the full article library, Asenapine: Labeled Uses and Safety for Adults | PHP/IOP MA, Citalopram: Labeled Uses and Safety for Adults | PHP/IOP MA.